Benefits and Harms of Antibiotic Use in End-of-Life Patients: Retrospective Study in Palliative Care

<b>Context:</b> Many patients at the end of life receive antibiotics to alleviate symptoms and improve quality of life; however, clear guidelines supporting decision making about the use of antibiotics are still lacking. <b>Objectives:</b> This study aimed to evaluate the benefits and harms of antibiotic use among patients under a palliative care community support team in Portugal. <b>Methods:</b> An observational, cross-sectional, retrospective study was conducted on 249 patients who died over a two-year period, having been followed for at least 30 days prior to their death. Data included patient demographics, clinical diagnoses, antibiotic prescriptions, and symptomatic outcomes. The effects of commonly prescribed antibiotics-amoxicillin + clavulanic acid, cefixime, ciprofloxacin, and levofloxacin-were compared using statistical analyses to assess survival, symptom intensity, and functional scales. <b>Results:</b> Adverse events, primarily infections and secretions, occurred in 57.8% of cases, with 33.7% receiving antibiotics. No significant difference in survival was observed across the antibiotic groups (<i>p</i> = 0.990). Symptom intensity significantly reduced after 72 h of treatment (<i>p</i> < 0.05), with ciprofloxacin demonstrating the greatest symptom control. The Palliative Outcome Scale decreased uniformly, with higher scores associated with amoxicillin + clavulanic acid (<i>p</i> = 0.004). The Palliative Performance Scale declined post-treatment, with significant changes noted for cefixime and ciprofloxacin (<i>p</i> < 0.05). <b>Conclusions:</b> Antibiotics may improve symptom control and quality of life in the end-of-life stage. While second-line antibiotics may offer additional benefits, the heterogeneity of the sample and limited adverse effect data underscore the need for further research to guide appropriate prescription practices in palliative care.